2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
8
Lymphoma, Follicular
8
Lymphoma
7
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell, Marginal Zone
5
Recurrence
4
Myeloproliferative Disorders
4
Lymphoma, Mantle-Cell
4
Primary Myelofibrosis
3
Hereditary Sensory and Autonomic Neuropathies
2
Breast Neoplasms
2
Advanced Malignancies
2
Unresectable or Metastatic Solid Tumors
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
346
Cytarabine
282
fludarabine phosphate
203
Methotrexate
186
Filgrastim
159
Busulfan
148
Etoposide
135
Peripheral Blood Stem Cell Transplantation
134
fludarabine
128
Rituximab
119
Radiotherapy
111
Vincristine
102
Cyclosporine
98
Daunorubicin
96
Antilymphocyte Serum
94
Dexamethasone
91
Tacrolimus
86
Mycophenolic Acid
86
Whole-Body Irradiation
81
Melphalan
79
Imatinib Mesylate
69
Idarubicin
67
Granulocyte Colony-Stimulating Factor
66
Mercaptopurine
65
Azacitidine
65
Methylprednisolone
59
Doxorubicin
58
Prednisone
57
Clofarabine
54
sargramostim
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
parsaclisib
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts